Advertisement

Do antihypertensive medications effect the mandibular cortical bone thickness? A study using cone beam computed tomography images

Published:April 04, 2022DOI:https://doi.org/10.1016/j.oooo.2022.03.015

      Objective

      The aim of this study was to measure the association between antihypertensive medication use and mandibular cortical thickness.

      Study Design

      This retrospective cross-sectional study was comprised of a study sample of 169 patients aged 40 to 69. Cone beam computed tomography scans were examined. The buccal cortical thickness of the mandibular ramus was measured. Participants were separated into the control or study group based on use of antihypertensive medications. The predictor variable was the use of antihypertensive medications. The primary outcome variable was cortical thickness of the mandible. Age was identified as a covariate affecting the outcome variable. The data was analyzed with a one-way analysis of covariance (ANCOVA) to remove the effect of age on the outcome variable. The groups were subdivided based on the sex of the patient.

      Results

      The study sample was composed of 169 patients with a mean age of 52.1, and 54% were female. There were 67 patients in the antihypertensive group (39.6%). A mean difference of 0.21 mm was found (P = .0010, 95% CI 0.09, 0.34 mm). The difference persisted after adjusting for age with one-way ANCOVA testing (P < .001).

      Conclusions

      This study suggests that there may be an association between antihypertensive use and mandibular cortical thickness. Age may be an effect modifier with the effect increasing in older patients.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      References

        • Kunutsor SK
        • Blom AW
        • Whitehouse MR
        • Kehoe PG
        • Laukkanen JA.
        Renin-angiotensin system inhibitors and risk of fractures: a prospective cohort study and meta-analysis of published observational cohort studies.
        Eur J Epidemiol. 2017; 32: 947-959
        • Ghosh M
        • Majumdar SR
        Antihypertensive medications, bone mineral density, and fractures: a review of old cardiac drugs that provides new insights into osteoporosis.
        Endocrine. 2014; 46: 397-405
        • Puttnam R
        • Davis BR
        • Pressel SL
        • et al.
        Association of 3 different antihypertensive medications with hip and pelvic fracture risk in older adults: secondary analysis of a randomized clinical trial.
        JAMA Internal Medicine. 2017; 177: 67-76
        • Hijazi N
        • Alourfi Z.
        Association between hypertension, antihypertensive drugs, and osteoporosis in postmenopausal syrian women: a cross-sectional study.
        Adv Med. 2020; 20207014212
        • Ağaçayak KS
        • Güven S
        • Koparal M
        • Güneş N
        • Atalay Y
        • Atılgan S.
        Long-term effects of antihypertensive medications on bone mineral density in men older than 55 years.
        Clin Interv Aging. 2014; 9: 509-513
        • Shimizu H
        • Nakagami H
        • Yasumasa N.
        Cilnidipine, but not amlodipine, ameliorates osteoporosis in ovariectomized hypertensive rats through inhibition of the N-type calcium channel.
        Hypertens Res. 2012; 35: 77-81
        • Lynn H
        • Kwok T
        • Wong SY
        • Woo J
        • Leung PC.
        Angiotensin converting enzyme inhibitor use is associated with higher bone mineral density in elderly Chinese.
        Bone. 2006; 38: 584-588
        • Shimizu H
        • Nakagami H
        • Osako MK.
        Prevention of osteoporosis by angiotensin-converting enzyme inhibitor in spontaneous hypertensive rats.
        Hypertens Res. 2009; 32: 786-790
        • Bolland MJ
        • Ames RW
        • Horne AM
        • Orr-Walker BJ
        • Gamble GD
        • Reid IR.
        The effect of treatment with a thiazide diuretic for 4 years on bone density in normal postmenopausal women.
        Osteoporos Int. 2007; 18: 479-486
        • Cheng L
        • Zhang K
        • Zhang Z.
        Effectiveness of thiazides on serum and urinary calcium levels and bone mineral density in patients with osteoporosis: a systematic review and meta-analysis.
        Drug Des Devel Ther. 2018; 12: 3929-3935
        • LaCroix AZ
        • Ott SM
        • Ichikawa L
        • Scholes D
        • Barlow WE.
        Low-dose hydrochlorothiazide and preservation of bone mineral density in older adults. A randomized, double-blind, placebo-controlled trial.
        Ann Intern Med. 2000; 133: 516-526
        • Reid IR
        • Ames RW
        • Orr-Walker BJ
        • et al.
        Hydrochlorothiazide reduces loss of cortical bone in normal postmenopausal women: a randomized controlled trial.
        Am J Med. 2000; 109: 362-370
        • Adams JS
        • Song CF
        • Kantorovich V.
        Rapid recovery of bone mass in hypercalciuric, osteoporotic men treated with hydrochlorothiazide.
        Ann Intern Med. 1999; 130: 658-660
        • Hernández JL
        • Valero C.
        Effect of beta-blockers on bone mineral density, bone turnover markers and fractures: a clinical review.
        Clin Rev Bone Miner Metab. 2015; 13: 185-193
        • Kwok T
        • Leung J
        • Zhang YF
        • et al.
        Does the use of ACE inhibitors or angiotensin receptor blockers affect bone loss in older men?.
        Osteoporos Int. 2012; 23: 2159-2167
        • Zacharieva S
        • Shigarminova R
        • Nachev E
        • et al.
        Effect of amlodipine and hormone replacement therapy on blood pressure and bone markers in menopause.
        Methods Find Exp Clin Pharmacol. 2003; 25: 209-213
        • Yang S
        • Nguyen ND
        • Center JR
        • Eisman JA
        • Nguyen TV.
        Association between hypertension and fragility fracture: a longitudinal study.
        Osteoporos Int. 2014; 25: 97-103
        • Bonnet N
        • Gadois C
        • McCloskey E
        • et al.
        Protective effect of beta blockers in postmenopausal women: influence on fractures, bone density, micro and macroarchitecture.
        Bone. 2007; 40: 1209-1216
        • Ezoddini-Ardakani F
        • Safi Y
        • Besharati S
        • Ebrahimi M
        • Safaee A.
        Evaluation of the effect of two classes of antihypertensive drugs on bone mineral density of the jaws in males over 50 years old in Yazd using cone beam computed tomography in 2015.
        JSSU. 2017; 25: 132-143
        • Demontiero O
        • Vidal C
        • Duque G.
        Aging and bone loss: new insights for the clinician.
        Ther Adv Musculoskelet Dis. 2012; 4: 61-76
        • Warming L
        • Hassager C
        • Christiansen C.
        Changes in bone mineral density with age in men and women: a longitudinal study.
        Osteoporos Int. 2002; 13: 105-112
        • Looker AC
        • Melton 3rd, LJ
        • Harris T
        • Borrud L
        • Shepherd J
        • McGowan J.
        Age, gender, and race/ethnic differences in total body and subregional bone density.
        Osteoporos Int. 2009; 20: 1141-1149
        • Boschitsch EP
        • Durchschlag E
        • Dimai HP.
        Age-related prevalence of osteoporosis and fragility fractures: real-world data from an Austrian Menopause and Osteoporosis Clinic.
        Climacteric. 2017; 20: 157-163
        • Lee J
        • Lee S
        • Jang S
        • Ryu OH.
        Age-related changes in the prevalence of osteoporosis according to gender and skeletal site: the Korea National Health and Nutrition Examination Survey 2008-2010.
        Endocrinol Metab (Seoul). 2013; 28: 180-191
        • Dorans KS
        • Mills KT
        • Liu Y
        • He J.
        Trends in prevalence and control of hypertension according to the 2017 American College of Cardiology/American Heart Association (ACC/AHA) Guideline.
        J Am Heart Assoc. 2018; 7e008888
        • Giro G
        • Chambrone L
        • Goldstein A
        • et al.
        Impact of osteoporosis in dental implants: a systematic review.
        World J Orthop. 2015; 6: 311-315
        • Ruggiero SL
        • Dodson TB
        • Fantasia J
        • et al.
        American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw—2014 update.
        J Oral Maxillofac Surg. 2014; 72: 1938-1956
        • Gelazius R
        • Poskevicius L
        • Sakavicius D
        • Grimuta V
        • Juodzbalys G.
        Dental implant placement in patients on bisphosphonate therapy: a systematic review.
        J Oral Maxillofac Res. 2018; 9: e2
        • de-Freitas NR
        • Lima LB
        • de-Moura MB
        • Veloso-Guedes CC
        • Simamoto-Júnior PC
        • de-Magalhães D.
        Bisphosphonate treatment and dental implants: a systematic review.
        Med Oral Patol Oral Cir Bucal. 2016; 21: e644-e651
        • Molly L.
        Bone density and primary stability in implant therapy.
        Clin Oral Implants Res. 2006; 17 (suppl): 124-135
        • Barikani H
        • Rashtak S
        • Akbari S
        • Badri S
        • Daneshparvar N
        • Rokn A.
        The effect of implant length and diameter on the primary stability in different bone types.
        J Dent (Tehran). 2013; 10: 449-455
        • Goiato MC
        • dos Santos DM
        • Santiago Jr, JF
        • Moreno A
        • Pellizzer EP
        • et al.
        Longevity of dental implants in type IV bone: a systematic review.
        Int J Oral Maxillofac Surg. 2014; 43: 1108-1116